See more : Orange S.A. (ORAN) Income Statement Analysis – Financial Results
Complete financial analysis of Myomo, Inc. (MYO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Myomo, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- RSD Finance Limited (RSDFIN.BO) Income Statement Analysis – Financial Results
- SKAN Group AG (SKAN.SW) Income Statement Analysis – Financial Results
- Lifetime Brands, Inc. (LCUT) Income Statement Analysis – Financial Results
- Landmark Cars Limited (LANDMARK.BO) Income Statement Analysis – Financial Results
- Aerius International, Inc. (AERS) Income Statement Analysis – Financial Results
Myomo, Inc. (MYO)
About Myomo, Inc.
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19.24M | 15.56M | 13.86M | 7.58M | 3.84M | 2.44M | 1.56M | 1.10M | 689.67K | 913.25K |
| Cost of Revenue | 6.06M | 5.30M | 3.54M | 2.60M | 917.62K | 728.28K | 505.28K | 282.16K | 244.41K | 211.58K |
| Gross Profit | 13.18M | 10.25M | 10.31M | 4.98M | 2.92M | 1.72M | 1.05M | 821.11K | 445.26K | 701.67K |
| Gross Profit Ratio | 68.51% | 65.91% | 74.42% | 65.71% | 76.09% | 70.20% | 67.59% | 74.42% | 64.56% | 76.83% |
| Research & Development | 2.64M | 2.48M | 2.56M | 1.67M | 2.16M | 1.84M | 1.75M | 1.12M | 869.13K | 675.21K |
| General & Administrative | 16.02M | 14.37M | 14.44M | 12.98M | 11.25M | 10.41M | 5.85M | 2.93M | 3.10M | 2.85M |
| Selling & Marketing | 3.22M | 4.07M | 3.59M | 841.30K | 301.70K | 136.30K | 31.00K | 41.60K | 119.70K | 14.30K |
| SG&A | 18.78M | 18.44M | 18.02M | 13.82M | 11.55M | 10.41M | 5.85M | 2.98M | 3.22M | 2.86M |
| Other Expenses | 0.00 | -1.10K | -16.95K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 21.41M | 20.93M | 20.58M | 15.49M | 13.72M | 12.24M | 7.60M | 4.10M | 3.98M | 3.44M |
| Cost & Expenses | 27.47M | 26.23M | 24.12M | 18.09M | 14.63M | 12.97M | 8.11M | 4.38M | 4.22M | 3.65M |
| Interest Income | 410.27K | 88.73K | 1.61K | 474.71K | 112.49K | 0.00 | 0.00 | 0.00 | 196.06K | 178.86K |
| Interest Expense | 0.00 | 88.73K | 15.34K | 474.71K | 113.63K | 358.92K | 358.92K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 517.68K | 542.63K | 335.96K | 108.67K | 95.12K | 69.68K | 11.42K | 7.73K | 5.31K | 6.16K |
| EBITDA | -7.71M | -10.13M | -9.93M | -11.24M | -10.70M | -10.46M | -6.54M | -3.27M | -3.53M | -2.74M |
| EBITDA Ratio | -40.09% | -65.12% | -71.68% | -137.06% | -283.88% | -429.40% | -86.36% | -296.14% | -511.58% | -299.50% |
| Operating Income | -8.23M | -10.67M | -10.27M | -10.50M | -10.80M | -10.53M | -6.55M | -3.28M | -3.53M | -2.74M |
| Operating Income Ratio | -42.78% | -68.61% | -74.10% | -138.50% | -281.29% | -430.77% | -420.06% | -296.84% | -512.35% | -300.17% |
| Total Other Income/Expenses | 239.99K | 21.12K | -15.34K | -1.06M | 81.99K | 211.68K | -5.55M | -342.02K | -196.06K | -178.86K |
| Income Before Tax | -7.99M | -10.65M | -10.28M | -11.56M | -10.71M | -10.32M | -12.10M | -3.62M | -3.73M | -2.92M |
| Income Before Tax Ratio | -41.53% | -68.47% | -74.21% | -152.49% | -279.15% | -422.11% | -776.04% | -327.84% | -540.77% | -319.76% |
| Income Tax Expense | 156.00K | 69.94K | 88.93K | 474.71K | -81.99K | -247.95K | 5.57M | 342.02K | 752.61K | 607.62K |
| Net Income | -8.15M | -10.72M | -10.37M | -12.04M | -10.63M | -10.32M | -12.10M | -3.62M | -4.48M | -3.53M |
| Net Income Ratio | -42.34% | -68.92% | -74.86% | -158.75% | -277.01% | -422.11% | -776.04% | -327.84% | -649.90% | -386.29% |
| EPS | -0.28 | -1.52 | -1.78 | -3.62 | -19.20 | -25.18 | -84.05 | -0.56 | -134.56 | -106.03 |
| EPS Diluted | -0.28 | -1.52 | -1.78 | -3.62 | -19.20 | -25.15 | -84.05 | -0.56 | -134.56 | -106.03 |
| Weighted Avg Shares Out | 29.50M | 7.05M | 5.83M | 3.33M | 553.79K | 409.75K | 143.93K | 6.41M | 33.31K | 33.27K |
| Weighted Avg Shares Out (Dil) | 29.50M | 7.05M | 5.83M | 3.33M | 553.79K | 410.15K | 143.93K | 6.41M | 33.31K | 33.27K |
Best Penny Stocks To Buy Under $1? 4 To Watch Now
Finding the best penny stocks to buy seems easy.
MyoPro Approved in Australia by National Disability Insurance Scheme
BOSTON--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, announced that for the first time, the National Disability Insurance Scheme (NDIS)...
Myomo Appoints Yitzchak Jacobovitz to its Board of Directors
BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the appointment of Yitzchak Jacobovitz as a Class...
4 Penny Stocks To Buy In January According To Insiders
Penny stocks to buy according to these insiders in January. The post 4 Penny Stocks To Buy In January According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Myomo Announces Closing of $6.5 Million Upsized Public Offering
BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the closing of its previously announced "best efforts"...
Myomo Announces Pricing of $6.5 Million Upsized Public Offering
BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced the pricing of its "best efforts" public offering...
Myomo Announces Initiative to Reduce Cash Burn
BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced a reduction in force for the purpose of...
Myomo Provides Update on Progress to Obtain Medicare Part B Reimbursement for MyoPro
BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today reported progress and next steps in the process to...
Ruling by German Social Court Supports MyoPro Reimbursement by Nation's Statutory Health Insurance System
BOSTON--( BUSINESS WIRE )--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that in an appeal before the Berlin-Brandenburg Regional...
Myomo, Inc. (MYO) Q3 2022 Earnings Call Transcript
Myomo, Inc. (NYSE:MYO ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 AM ET Company Participants Kim Golodetz - Investor Relations, LHA Paul Gudonis - Chief Executive Officer Dave Henry - Chief Financial Officer Conference Call Participants Ben Haynor...
Source: https://incomestatements.info
Category: Stock Reports